Comparison of Carboplatin With Cisplatin in Small Cell Lung Cancer in US Veterans.

ABSTRACT:

Importance

The current standard of care for the treatment of small cell lung cancer (SCLC) is concurrent chemoradiation for patients with limited-stage SCLC (LS-SCLC) and chemoimmunotherapy for extensive-stage SCLC (ES-SCLC). The backbone of chemotherapy regimens in both is a platinum-etoposide doublet: cisplatin is traditionally the preferred platinum agent in the curative intent setting, whereas carboplatin is preferred in ES-SCLC because of its favorable toxicity profile.

Objective

To determine whether cisplatin is associated with better survival outcomes than carboplatin in treating LS-SCLC and ES-SCLC.

Design, setting, and participants

In this cohort study, data were compiled from the National Veterans Affairs Central Cancer Registry for patients with SCLC who re

SUBMITTER: Azar I 

PROVIDER: S-EPMC9585434 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature